Jio Financial Services, the separate entity of Reliance Industries Ltd (RIL) led by Mukesh Ambani, is scheduled to be listed on August 21. This announcement follows a recent statement by FTSE that JFS will be delisted from FTSE indices on August 22 due to the lack of communication about the listing date.

According to a filing with the stock exchange, the company mentioned that the stock would be part of the Trade-for-Trade segment for a duration of 10 trading days.

On August 2, 2023, 17 stocks are scheduled to trade ex-dividend. This date is significant for investors as it marks when a company's shares begin trading without factoring in the value of the next dividend payment. In practical terms, investors who own the stock before the ex-dividend date will receive the upcoming dividend payment. At the same time, those who purchase it on or after the ex-dividend date will not be eligible for the dividend.

The IPO of Concord Biotech Limited is scheduled to open from 4th August to 8th August 2023. Concord Biotech is an India-based R&D-led biopharma company. The IPO includes an Offer-for-Sale (OFS) of 20,925,652 equity shares amounting to ₹1551 crore. The share allotment date is 11th August, and the IPO is set to be listed on 18th August on the stock exchanges. The price band for the IPO is ₹705 to ₹741, and the IPO size is 20 shares.

The book-running lead managers for this IPO are Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, and Jefferies India Private Limited. The registrar for the IPO is Link Intime India Private Limited.

API Holdings, the parent company of PharmEasy, has filed a Draft Red Herring Prospectus (DRHP) with SEBI for an initial public offering (IPO) worth Rs. 6250 crores. The IPO was filed on 11th November 2021, and it plans to raise funds through fresh equity issuance.

In addition to the IPO, the company is also in discussions with its bankers for pre-IPO fundraising through private placement, aiming to raise a total amount of Rs. 1250 crores. This move will significantly reduce the main issue size.